Log in

NASDAQ:HCMHUTCHISON CHINA/S Stock Price, Forecast & News

$22.38
+0.39 (+1.77 %)
(As of 06/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$21.56
Now: $22.38
$22.68
50-Day Range
$18.29
MA: $21.04
$22.50
52-Week Range
$14.74
Now: $22.38
$30.30
Volume419,731 shs
Average Volume313,304 shs
Market Capitalization$2.99 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.12
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, a c-MET inhibitor for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, a inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; and HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma, as well as HMPL-689, a treatment for indolent non-Hodgkin's lymphoma and healthy volunteers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.
Read More
HUTCHISON CHINA/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HCM
CUSIPN/A
Phone852-2121-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$204.89 million
Book Value$2.35 per share

Profitability

Miscellaneous

Employees714
Market Cap$2.99 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive HCM News and Ratings via Email

Sign-up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.

HUTCHISON CHINA/S (NASDAQ:HCM) Frequently Asked Questions

How has HUTCHISON CHINA/S's stock been impacted by COVID-19 (Coronavirus)?

HUTCHISON CHINA/S's stock was trading at $23.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HCM shares have decreased by 2.9% and is now trading at $22.38. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of HUTCHISON CHINA/S?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HUTCHISON CHINA/S in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for HUTCHISON CHINA/S.

What price target have analysts set for HCM?

5 equities research analysts have issued twelve-month price objectives for HUTCHISON CHINA/S's shares. Their forecasts range from $29.00 to $29.00. On average, they anticipate HUTCHISON CHINA/S's share price to reach $29.00 in the next twelve months. This suggests a possible upside of 29.6% from the stock's current price. View analysts' price targets for HUTCHISON CHINA/S.

Has HUTCHISON CHINA/S been receiving favorable news coverage?

Media stories about HCM stock have been trending very negative on Wednesday, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. HUTCHISON CHINA/S earned a media sentiment score of -3.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutHUTCHISON CHINA/S.

Who are some of HUTCHISON CHINA/S's key competitors?

What other stocks do shareholders of HUTCHISON CHINA/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHISON CHINA/S investors own include Telford Homes (TEF), Premier Oil (PMO), GW Pharmaceuticals PLC- (GWPH), AbbVie (ABBV), Crispr Therapeutics (CRSP), Exelixis (EXEL), AT&T (T), Alibaba Group (BABA), Gilead Sciences (GILD) and Johnson & Johnson (JNJ).

Who are HUTCHISON CHINA/S's key executives?

HUTCHISON CHINA/S's management team includes the following people:
  • Mr. Chi Keung To B.Sc., M.B.A., BSc, ACGI, MBA, Exec. Chairman (Age 67)
  • Mr. Christian Hogg B.Sc., M.B.A., BSc, MBA, CEO & Exec. Director (Age 53)
  • Mr. Johnny Cheng C.A., BEc, CA, CFO & Exec. Director (Age 52)
  • Dr. Weiguo Su B.Sc., Ph.D., Chief Scientific Officer, Exec. VP & Exec. Director (Age 62)
  • Ms. Edith Shih B.S., M.A., BSE, MA, EdM, Solicitor, FCIS, FCS(PE), Company Sec. & Non-Exec. Director (Age 67)

When did HUTCHISON CHINA/S IPO?

(HCM) raised $100 million in an initial public offering on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities served as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

What is HUTCHISON CHINA/S's stock symbol?

HUTCHISON CHINA/S trades on the NASDAQ under the ticker symbol "HCM."

Who are HUTCHISON CHINA/S's major shareholders?

HUTCHISON CHINA/S's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Schroder Investment Management Group (2.99%), M&G Investment Management Ltd. (2.92%), Invesco Ltd. (2.72%), BlackRock Inc. (2.36%), Capital International Investors (2.28%) and Sands Capital Management LLC (1.78%).

Which major investors are selling HUTCHISON CHINA/S stock?

HCM stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., AIA Investment Management Private Ltd, Canada Pension Plan Investment Board, Morgan Stanley, Capital Bank & Trust Co, UBS Group AG, SG Americas Securities LLC, and Citigroup Inc..

Which major investors are buying HUTCHISON CHINA/S stock?

HCM stock was purchased by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Capital International Investors, Sands Capital Management LLC, JPMorgan Chase & Co., M&G Investment Management Ltd., BlackRock Inc., State Street Corp, and Sumitomo Mitsui Trust Holdings Inc..

How do I buy shares of HUTCHISON CHINA/S?

Shares of HCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is HUTCHISON CHINA/S's stock price today?

One share of HCM stock can currently be purchased for approximately $22.38.

How big of a company is HUTCHISON CHINA/S?

HUTCHISON CHINA/S has a market capitalization of $2.99 billion and generates $204.89 million in revenue each year. The company earns $-106,020,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. HUTCHISON CHINA/S employs 714 workers across the globe.

What is HUTCHISON CHINA/S's official website?

The official website for HUTCHISON CHINA/S is www.chi-med.com.

How can I contact HUTCHISON CHINA/S?

HUTCHISON CHINA/S's mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The company can be reached via phone at 852-2121-8200 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.